IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
21.85
+0.12 (0.55%)
Feb 21, 2025, 4:00 PM EST - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 124 employees as of December 31, 2023. The number of employees increased by 21 or 20.39% compared to the previous year.
Employees
124
Change (1Y)
21
Growth (1Y)
20.39%
Revenue / Employee
$56,452
Profits / Employee
-$2,213,524
Market Cap
1.91B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
IDYA News
- 9 days ago - IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 9 days ago - IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PRNewsWire
- 11 days ago - Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha
- 12 days ago - IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PRNewsWire
- 22 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 26 days ago - IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PRNewsWire